---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003380"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:31:48.544134+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase

## Summary
- Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.
- Atreca antibody purchase: $5.5M cash upfront, $7M milestones for over 25 preclinical antibodies; closing subject to shareholder approval.
- IND filings planned for 1Q 2025 for FAP radioligand therapy, ROR1 ADC (IM-1021), and IL-38 immunotherapy.
- AbbVie collaboration: $30M upfront, up to $70M platform payments, $120M per target milestones, $150M per target sales milestones.
- Preclinical data shows IM-1021 superior to MK-2140 in TNBC model; proprietary payload outperforms Enhertu in HER2-low model.

## SEC filing metadata
- accession: 0001104659-24-003380
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/0001104659-24-003380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/tm242340d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003380
- JSON: https://secwatch.observer/filing/0001104659-24-003380.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.